This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.
LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Set to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2023 results are likely to reflect an impressive performance across the Healthcare and AST segments, with a gradual improvement in the supply chain.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings
by Zacks Equity Research
Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.
BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.
Neogen (NEOG) New Buyouts Aid Growth Amid Rise in Expenses
by Zacks Equity Research
Neogen's (NEOG) performance of the Food Safety business is strong, driven by several long-term secular tailwinds.
AmerisourceBergen's (ABC) New JV to Boost Oncology Care
by Zacks Equity Research
AmerisourceBergen's (ABC) new JV is expected to provide the independent community oncology network with additional resources and expertise to grow the platform and improve patient outcomes.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
What's in Store for West Pharmaceutical (WST) in Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.
IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.
Henry Schein (HSIC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Henry Schein (HSIC) closed at $83.01, marking a +0.07% move from the previous day.
Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.
Masimo's (MASI) New FDA Approval to Improve Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.
Baxter (BAX) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.